质粒pIRES/VEGF165/HGF治疗重症肢体缺血的临床研究
该研究在12例重症肢体缺血患者的12条患肢缺血肌肉内注射pIRES/VEGF165/HGF质粒,观察安全性与疗效。治疗后3个月踝肱指数(ABI)从0.27±0.20显著升至0.50±0.22(P<0.001),9条患肢缺血性溃疡愈合,3例因晚期坏死和伤口感染截肢但截肢平面降至膝下。结论认为该基因治疗安全、可行且有效。
要点
- 缺血肌肉内注射pIRES/VEGF165/HGF质粒可使重症肢体缺血患者ABI显著改善
- 12条患肢中9条缺血性溃疡愈合,3例截肢但平面降至膝下
- 并发症仅为一过性下肢水肿和发热,未见严重不良事件
核心结论
- 肌肉内注射pIRES/VEGF165/HGF质粒对重症肢体缺血患者安全、可行且有效。
研究设计与样本
- 研究纳入12例因重症肢体缺血出现静息痛和缺血性溃疡的患者,共12条患肢。
- 将pIRES/VEGF165/HGF质粒注射至缺血肢体肌肉内,治疗前后检测血清VEGF水平和ABI。
主要发现
- 治疗后2周血清VEGF平均水平从258±81 pg/L升至489±96 pg/L,差异无统计学意义(P>0.05)。
- 治疗后3个月ABI从0.27±0.20显著改善至0.50±0.22(P<0.001)。
- 12条患肢中9条缺血性溃疡愈合;3例因晚期坏死和伤口感染行截肢,但截肢平面降至膝下。
- 并发症限于3例一过性下肢水肿和2例发热。
临床怎么用
- 对于不适合或无法行血运重建的重症肢体缺血患者,可考虑肌肉内注射pIRES/VEGF165/HGF质粒作为治疗选择。
- 治疗期间应监测ABI和血清VEGF水平,并观察溃疡愈合情况及下肢水肿、发热等不良反应。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Prognosis of peripheral artery disease (PAD), especially critical limb ischemia (CLI), is very poor despite the development of endovascular therapy and bypass surgery. Many patients result in having leg amputation. We decided to investigate the safety and efficacy of plasmid of internal ribosome entry site/vascular endothelial growth factor (VEGF) 165/hepatocyte growth factor (HGF) gene therapy (GT) in patients suffered from CLI. METHODS: Administration of plasmid of internal ribosome entry site/VEGF165/HGF was performed in 12 limbs of 12 patients with rest pain and ischemic ulcers due to CLI. Plasmid was injected into the muscles of the ischemic limbs. The levels of VEGF in serum and the ankle-brachial index (ABI) were measured before and after treatment. RESULTS: Mean (±SD) plasma levels of VEGF increased nonsignificantly from 258 ± 81 pg/L to 489 ± 96 pg/L (P > 0.05) 2 weeks after therapy, and the ABI improved significantly from 0.27 ± 0.20 to 0.50 ± 0.22 (P < 0.001) 3 months after therapy. Ischemic ulcers healed in 9 limbs. Amputation was performed in 3 patients because of advanced necrosis and wound infection. However, the level of amputations was lowered below knee in these cases. Complications were limited to transient leg edema in 3 patients and fever in 2 patients. CONCLUSIONS: Intramuscular administration of plasmid of internal ribosome entry site/VEGF165/HGF is safe, feasible, and effective for patients with critical leg ischemia.
引用
- Barć P, Antkiewicz M, Śliwa B, et al. Treatment of Critical Limb Ischemia by pIRES/VEGF165/HGF Administration. Ann Vasc Surg. 2019. PMID: 31200059. doi:10.1016/j.avsg.2019.03.013
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。